Intimation of Book Closure date July 24, 2025, to July 31, 2025 (both days inclusive)
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India's board, at its May 9, 2025 meeting, approved audited FY25 results showing revenue from operations of ₹3,562.7 million (up from ₹3,350.7 million in FY24) and net profit of ₹1,009.0 million (up from ₹851.9 million), with EPS of ₹40.87 vs ₹34.50. The board recommended a final dividend of ₹25 per equity share (face value ₹5), unchanged from last year, subject to shareholder approval at the 77th AGM on July 31, 2025. The register of members will be closed from July 24 to July 31, 2025 to determine dividend eligibility. Additionally, Mr. Sanker Parameswaran was re-appointed as Independent Director for a second 5-year term, M.K Saraf & Associates LLP was appointed as Secretarial Auditor for 5 years, and a postal ballot was cleared for related party transactions with Novartis Pharma AG.
Shareholders holding shares as of the record date (within the July 24-31 book closure window) will be eligible for the ₹25 per share dividend. Profit growth of around 18% with a maintained dividend signals stable shareholder returns, though the unchanged dividend amount means no incremental yield benefit compared to the prior year.